Founded in 2014, aptaTargets was spun-out of Aptus Biotech, an aptamer technology platform. aptaTargets started a drug development program collaborating with the Complutense University and the Ramon y Cajal Hospital.
In 2019 and 2020, aptaTargets conducted the First-in-Human clinical trial in healthy volunteers (NCT04742062). A Phase Ib/IIa trial in acute ischemic stroke patients is currently in progress (APRIL study, NCT04734548), with the Phase Ib portion completed in June 2021.
aptaTargets raised a Series B round in 2020, from Inveready Asset Management and the CDTI (Centre for the Development of Industrial Technology), through the INNVIERTE program.